-
-
Cancer Networks
The cancer networks came into being following the recommendations in the Calman Hine report
Facilitatory, advisory and supportive role
Non-statutory organisations that will continue to exist following the most recent changes -
Improving outcomes guidance
Improving outcomes guidance. Started by DH in 1996 but taken under the auspices of nice in 2000.
Implemented to provide site by site guidances on the best practices for patient pathways.
This was because services were fragented and disorganised.
Each IOG intends to change and streamline quality services. -
NCAT
- Established in the late 1990s and was part of the team given the task of implementing the Calman Hine Programme
- Current aim is to support the NHS in translating ‘Improving Outcomes: A Strategy for Cancer’ into reality.
- By supporting cancer networks in the development of early diagnosis initiatives through to developing better information for cancer patients, NCAT works across the cancer patient pathway.
-Important role in delivering the Peer Review Programme -
NICE The National Institute for Health and Clinical Excellence (NICE) was
established in 1999 NICE makes recommendations to the NHS on:
new and existing medicines, treatments and procedures
treating and caring for people with specific diseases and conditions. “We make independent decisions in an open, transparent way, based on the best available evidence and including input from experts and interested parties”. -
NCPR
- A national quality assurance programme for NHS cancer services.- Provides commissioners, providers, statutory regulators and service users with an independent, comprehensive disease specific profile of individual teams and services across England
- Involves self-assessment by cancer service teams and external reviews conducted by peers, against nationally agreed “quality measures”.
-
Guidance published in response to
- fragmented and uncoordinated pathway of care
- resources were directed into tackling the bigger name cancers Key recommendations
- establishment of direct referral pathways
- setting up multidisciplinary teams of neurosurgeons oncologists, pathologists and radiologists to review diagnoses and determine the best type of treatment. -
£200 million is being made available in each of the next three years (from 2011/12) by the Coallition
To be used to fund drug treatments, including radiopharmaceuticals for patients who have been unable to access a drug recommended by their oncologist. This may include:
drug / indication combinations on which NICE has not, or not yet, issued appraisal guidance
drug / indication combinations appraised by NICE and not recommended on the basis of cost effectiveness,
